Spatz Medical Marks Milestone: Spatz3 Adjustable Gastric Balloon Launches in the U.S. in March 2024
FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Spatz Medical, a global leader in gastrointestinal weight loss solutions, is delighted to announce the commencement of commercialization of the Spatz3 Adjustable Gastric Balloon.
- FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Spatz Medical, a global leader in gastrointestinal weight loss solutions, is delighted to announce the commencement of commercialization of the Spatz3 Adjustable Gastric Balloon.
- The Spatz3 Adjustable Gastric Balloon, renowned as the first and only adjustable gastric balloon, has earned widespread acclaim for its outstanding weight loss results and an impressive 84% success rate, as demonstrated in the FDA Pivotal trials and real-world applications.
- For the first time in gastric balloon history, an adjustable gastric balloon affords patients a decision making role in their weight loss therapy, customized to their needs.
- For more information about Spatz Medical and the Spatz3 Adjustable Gastric Balloon, please visit www.SpatzMedical.com.